Accessibility Menu
 
Lisata Therapeutics logo

Lisata Therapeutics

(NASDAQ) LSTA

Current Price$5.01
Market Cap$45.34M
Since IPO (1991)-100%
5 Year-82%
1 Year+143%
1 Month+16%

Lisata Therapeutics Financials at a Glance

Market Cap

$45.34M

Revenue (TTM)

$170.00K

Net Income (TTM)

$16.59M

EPS (TTM)

$-1.91

P/E Ratio

-2.63

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Price

$5.01

Volume

15,337

Open

$5.01

Previous Close

$5.02

Daily Range

$5.01 - $5.03

52-Week Range

$1.81 - $5.07

LSTA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lisata Therapeutics

Industry

Biotechnology

Employees

21

CEO

David J. Mazzo, PhD

Headquarters

Basking Ridge, NJ 07920, US

LSTA Financials

Key Financial Metrics (TTM)

Gross Margin

91%

Operating Margin

-107%

Net Income Margin

-98%

Return on Equity

-75%

Return on Capital

-1%

Return on Assets

-93%

Earnings Yield

-38.02%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$45.34M

Shares Outstanding

9.03M

Volume

15.34K

Short Interest

0.00%

Avg. Volume

171.38K

Financials (TTM)

Gross Profit

$24.00K

Operating Income

$18.21M

EBITDA

$18.06M

Operating Cash Flow

$15.95M

Capital Expenditure

$28.00K

Free Cash Flow

$15.98M

Cash & ST Invst.

$15.96M

Total Debt

$0.00

Lisata Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$100.00K

-90.0%

Gross Profit

$85.00K

-91.5%

Gross Margin

85.00%

N/A

Market Cap

$45.34M

N/A

Market Cap/Employee

$1.74M

N/A

Employees

26

N/A

Net Income

$2.95M

+35.9%

EBITDA

$3.06M

+37.6%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$15.96M

-48.7%

Accounts Receivable

$700.00K

-22.2%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-93.47%

N/A

Return on Invested Capital

-1.24%

N/A

Free Cash Flow

$3.25M

+28.2%

Operating Cash Flow

$3.25M

+28.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
XCURExicure, Inc.
$4.19+0.24%
PASGPassage Bio, Inc.
$8.08+2.93%
ENLVEnlivex Therapeutics Ltd.
$0.95-1.07%
KLTOKlotho Neurosciences, Inc.
$0.38-7.10%

Trending Stocks

Symbol / CompanyPricePrice Chg
SKYQSky Quarry
$5.10+1.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.37-0.11%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.33+0.00%
NOKNokia
$8.82+0.07%

Questions About LSTA

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.